Taiho Oncology
↗Princeton, New Jersey, USA
Taiho Oncology is a leading clinical development and commercialization organization specializing in novel anti-cancer therapeutics, with a focus on orally administered small-molecule agents for solid tumors and hematological malignancies. The company has successfully commercialized three FDA-approved oncology drugs (LONSURF, INQOVI, and LYTGOBI) and maintains a robust pipeline of investigational candidates in Phase 2 and Phase 3 development. As a subsidiary of Taiho Pharmaceutical (owned by Otsuka Holdings), Taiho Oncology benefits from significant R&D and capital resources while maintaining focused operations as a specialized oncology CRO/commercial entity.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2002
Ownership:private_subsidiary
Status:operating
FUNDING
Stage:fully_funded_by_parent
Investors:Taiho Pharmaceutical Co., Ltd., Otsuka Holdings Co., Ltd.
PIPELINE
Stage:Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3
Modalities:Small molecule, Oral anti-cancer agents, Tyrosine kinase inhibitors (TKI)
Active Trials:84
Trial Phases:Phase 3: 1
FDA Approvals:3
CORPORATE STRUCTURE
Parent Company:Taiho Pharmaceutical Co., Ltd. (owned by Otsuka Holdings Co., Ltd.)
Key Partnerships:Cullinan Therapeutics (Zipalertinib co-development), Araris Biotech (acquired for up to $1.1B for ADC technology), Taiho Ventures (investment arm with $400M fund), NIH/National Cancer Institute (myeloMATCH precision medicine trials)
COMPETITION
Position:Niche Player|Challenger
Competitors:Amgen, AstraZeneca, Bristol Myers Squibb, Roche, Celgene, Juno Therapeutics, Citius Oncology, OnCusp Therapeutics
LEADERSHIP
Key Executives:
Peter Melnyk - President & Chief Executive Officer
Michael - Chief Business Officer
Kazu - Senior Vice President, Finance
Volker - Head of Clinical Development
Ed - VP, Chief Information Officer
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Taiho Oncology and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Taiho Oncology. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.